Ambramed - Company finances
|
EUR
|
2021
From: 2021-07-07
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | - | 2,280 | 16,875 | 40,122 |
| Profit before tax | - | - | - | - | - |
| Net profit | -13 | 0 | 228 | 3,023 | 11,937 |
| Equity | -13 | 87 | 314 | 3,337 | 15,274 |
| Liabilities | 350 | 225 | 2,805 | 2,980 | 762 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 337 | 312 | 3,119 | 6,317 | 16,036 |
| Total assets | 337 | 312 | 3,119 | 6,317 | 16,036 |
|
Taxes paid
|
|||||
| STI taxes | - | - | - | 11 | 159 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | - | +640.1% | +137.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -3.9% | 0.0% | 7.3% | 47.9% | 74.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 0.0% | 72.6% | 90.6% | 78.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | 10.0% | 17.9% | 29.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 2.6 | 8.9 | 0.9 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ambramed - Social security debts
The company had no debts to Sodra
Ambramed - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ambramed, MB (code 305819234) is a Small partnership active in other human health activities n.e.c. In 2025, the company generated revenue of €40.1K and net profit of €11.9K, with a profit margin of 29.8%. Revenue increased by 137.8% year on year, while the two-year increase reached 1659.7%, showing a very strong expansion from €2.3K in 2023 to €16.9K in 2024 and then to the latest level in 2025. Profitability improved in parallel, rising from €228 in 2023 to €3.0K in 2024 and €11.9K in 2025. The balance sheet remained solid, with total assets of €16.0K, equity of €15.3K and liabilities of only €762 at the end of 2025. The equity ratio stood at 95.2% and debt-to-equity at 0.05, indicating a lightly leveraged structure. Asset turnover was 2.50x, reflecting efficient use of assets. Overall, 2025 marked a year of rapid growth and strong profitability.